AAP
KLRS

Arax Advisory Partners’s Kalaris Therapeutics KLRS Stock Holding History

Arax Advisory Partners’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$365 – 2794
2024
Q3 		$365 Hold
20
– – ﹤0.01% 2447
2024
Q2 		$327 Buy
+20
New +$353 ﹤0.01% 2387

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's KLRS Position: Q4 2024 in Review

Arax Advisory Partners sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 20 shares — an estimated $365 sold.

Arax Advisory Partners first reported a position in KLRS in Q2 2024 and held it in 2 quarters. The position peaked at $365 in Q3 2024. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Arax Advisory Partners reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 20 Kalaris Therapeutics shares in Q4 2024, an estimated $365.
  • Arax Advisory Partners first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Kalaris Therapeutics position peaked at $365 in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.